Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Evotec SE
2023 · Co-Development · $4.0B · Complete
Announcement Sentiment
92
Strongly positive
Outcome Score
66
Largely worked — most objectives met.
BMS extended and expanded its strategic neurodegeneration partnership with Evotec for 8 additional years, building on their 2016 collaboration including clinical-stage EVT8683.
Key facts
Announced Mar 28, 2023 Closed Mar 28, 2023 Deal value $4.0B Deal type Co-Development Therapeutic area Neurology Indications Neurodegenerative diseases Key assets EVT8683 Mechanism Undisclosed neurodegeneration targets
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About